Excessively Low Drug Prices in Japan Are Shrinking the Market and May Ultimately Harm Patients
AI summary card
Excessively Low Drug Prices in Japan Are Shrinking the Market and May Ultimately Harm Patients
As the world’s fourth-largest pharmaceutical market, Japan’s aggressive government cost controls have driven drug prices to the lowest among major developed markets, pushing domestic firms overseas; over the long term, low returns are suppressing the launch and development of innovative drugs in Japan.
- Japanese drug prices are only 22% of U.S. levels—the lowest among major developed markets
- The Japanese government strictly controls drug prices through annual adjustments and penalties for exceeding sales forecasts
- Despite a patent-term price maintenance program, drugs face steep one-time price cuts after protection expires
- New drug approvals and R&D investment in Japan have declined over the past decade
- Major Japanese pharma companies (e.g., Takeda, Daiichi Sankyo) now rely on overseas operations as their primary growth engine
Report interpretation
Overview
This report provides an in-depth analysis of Japan’s drug pricing system and its negative effects on the pharmaceutical industry. Although Japan boasts one of the world’s longest-lived populations and an efficient healthcare system, the government has used drug pricing as its main lever to control healthcare spending amid fiscal pressures from rapid aging. The report notes that Japan has the lowest drug prices among major developed markets. While this helps contain costs in the short term, it is eroding the market’s attractiveness over the long term, reducing new drug approvals and R&D investment, and ultimately limiting patient access to innovative therapies.
Core views
Japan’s position in the global pharmaceutical market has significantly declined. In 2024, Japan became the world’s fourth-largest pharmaceutical market, with a size less than one-tenth that of the U.S. ($68 billion vs. $812 billion)—down from one-third in 2012. Among major markets, Japan exhibits the weakest growth, even recording negative growth between 2010 and 2020. Aggressive government cost containment has driven drug prices to global lows. With the world’s fastest-aging population and the government covering about 38% of total healthcare expenditures, cost control is a top priority. Although pharmaceutical spending accounts for only 16% of total healthcare outlays, drugs have become the primary target for savings due to the government’s full pricing authority and limited political resistance. Currently, Japanese drug prices stand at just 22% of U.S. levels—on par with France and far below other developed countries. The pricing mechanism is complex and stringent. New drug pricing primarily uses the 'comparable drug method' (65% of cases), granting premiums based on innovation and therapeutic value; if no comparable exists, the 'cost-plus method' applies (26%). Additional premiums exist for orphan drugs, pediatric medicines, and Japan-first launches. However, post-launch prices face dual pressures: annual downward adjustments based on actual transaction prices (averaging a 0.9% cut in FY2026); and special price reductions of 10–50% if sales significantly exceed initial peak forecasts (e.g., Daiichi Sankyo’s Lixiana faced two such cuts). Innovation protection and long-term concerns. While the 'Patent Term Price Maintenance Program' (PMP) exempts innovative drugs from annual price cuts for up to 15 years post-generic entry or during patent life, a one-time catch-up price reduction occurs once protection ends. More concerning, low returns are already having real consequences: over the past decade, new drug approvals in Japan have steadily declined while those in the U.S., China, and Europe have risen; pharmaceutical R&D spending in Japan has also shrunk, reaching only ~$10 billion in 2023—far below the U.S.’s $70 billion. If the U.S. implements 'Most Favored Nation' drug pricing provisions, multinational companies may further delay or abandon Japan launches, leaving Japanese patients without timely access to cutting-edge therapies.
Analysis framework
The report employs a combined macro-micro analytical framework. First, it compares the size, growth rates, and relative drug prices (as a percentage of U.S. prices) across major global pharmaceutical markets to establish Japan’s ‘low-growth, low-price’ fundamentals. Second, it dissects the pricing rules set by Japan’s Ministry of Health, Labour and Welfare (MHLW)—including initial pricing methodologies, annual adjustments, sales-over-performance penalties, and cost-effectiveness evaluations—to reveal specific cost-containment tools. Finally, it tracks trends in new drug approvals, R&D spending, and the rising share of overseas revenue among major Japanese pharma firms to demonstrate how low drug prices are eroding long-term innovation incentives.
Methodology notes
Policy-Induced Supply-Side Constraints
The report analyzes how government pricing policies (strong demand-side payer intervention) suppress pharmaceutical companies’ (supply-side) willingness to invest in innovation and launch new drugs, thereby degrading the quality of market supply.
Volume-Price Analysis of Pharmaceutical Spending in Healthcare Expenditure
The report breaks down healthcare spending into inpatient care, outpatient care, and pharmaceuticals, noting that although drugs account for only 16% of total spending, their high price elasticity and government controllability make them the primary focus for cost containment.
Profit Margin Compression in Distribution Channels
The report notes intense competition among Japanese wholesalers drives pharmacy procurement prices downward, widening the gap with official reimbursement prices and triggering annual government price cuts to compress distribution margins.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Daiichi Sankyo (4568.JP)Negatively Impacted/Under Pressure
- Strengths
- Strong overseas growth (11% CAGR), leadership in oncology pipeline
- Weaknesses
- Flagship product Lixiana suffered two major price cuts (28% and 20%) due to exceeding sales forecasts
- Comparison
- Higher international exposure compared to purely domestic peers enhances resilience
- Risks
- Future blockbuster drugs launched in Japan still face special price-cut risks if sales exceed projections
- Eisai (4523.JP)Negatively Impacted/Under Pressure
- Strengths
- Owns blockbuster Alzheimer’s drug Leqembi
- Weaknesses
- Leqembi was forced to accept a 15% price cut due to unfavorable cost-effectiveness assessment, highlighting pricing pressure on high-cost drugs
- Comparison
- Premium pricing power for innovative drugs is directly challenged by government cost-effectiveness reviews
- Risks
- Tension between high R&D investment and constrained pricing for breakthrough therapies
- Takeda (4502.JP)Beneficiary/Transformation
- Strengths
- Extremely high overseas revenue share; 15% CAGR internationally from 2016–2022, with flat domestic performance
- Weaknesses
- Stagnant growth in the domestic market
- Comparison
- A textbook example of using globalization to offset domestic pricing pressures
- Risks
- Intensifying global competition
- Astellas (4503.JP)Negatively Impacted/Under Pressure
- Strengths
- Early international expansion
- Weaknesses
- Domestic business shrank severely, with a -9% CAGR from 2016–2022
- Comparison
- Faster domestic decline than peers
- Risks
- Over-reliance on overseas markets exposes the company to currency and regulatory risks
Key data
- Japan Pharmaceutical Market Size in 2024$68 billionLess than one-tenth the size of the U.S. market ($812 billion)
- Japan Drug Prices Relative to U.S. Levels22%Lowest among major developed markets, on par with France
- Government Share of Healthcare Expenditure38%Shared between national and local governments, creating pressure for cost containment
- Average Drug Price Reduction in FY20260.9%Determined based on a 4.8% gap between actual transaction prices and official reimbursement prices
- Eisai’s Leqembi Price Cut15%Mandated in November 2025 after failing cost-effectiveness evaluation
- Japan’s Pharmaceutical R&D Spending in 2023~$10 billionDeclining trend, far below the U.S. (~$70 billion) and China (~$15 billion)
Impact & implications
For Japanese pharmaceutical companies, the domestic market no longer offers sufficient growth potential, making international expansion inevitable. Data shows that global giants like Takeda, Daiichi Sankyo, and Astellas have achieved significantly higher compound annual growth rates (CAGRs) overseas than domestically, with some even reporting negative growth at home. For multinational companies, Japan’s declining return on investment may lead them to delay or skip launching innovative drugs there, prioritizing higher-value markets like the U.S. For patients, while low drug prices ease short-term burdens, they risk a future where effective treatments exist globally but remain inaccessible in Japan, causing missed opportunities for optimal care.
Risks
- Further tightening of Japan’s pricing rules, including shortening the price protection period for innovative drugs
- Implementation of U.S. Most Favored Nation drug pricing clauses, potentially causing multinationals to exit the Japanese market entirely
- Yen exchange rate volatility affecting the translated value of overseas earnings for Japanese pharma firms
- Rising R&D failure rates combined with low returns leading to industry-wide investment contraction
What to watch
- Annual drug price adjustment magnitude and new regulations from Japan’s Ministry of Health, Labour and Welfare (MHLW)
- Delays in new drug launches in Japan by multinational companies
- Trends in overseas revenue share among major Japanese pharmaceutical firms
- Expansion of cost-effectiveness evaluation (ICER) application to high-priced drug pricing decisions